Hospitals Spent 20 Years Buying Doctors' Offices. Medicare Just Broke the Math.
Medicare's proposed 2027 outpatient rule guts the two markups that built the modern hospital conglomerate — the facility fee and the 340B drug spread. Budget neutrality means the money doesn't vanish; it moves. Here's who collects.
On July 2, while markets were busy with earnings season, the Centers for Medicare & Medicaid Services dropped a 1,000-plus-page proposed rule that goes after the two quiet markups underwriting the modern American hospital system. The comment period closes August 31. The policies take effect January 1, 2027. And almost nobody outside health policy circles has priced what they do to a $1.5 trillion industry's business model.
For twenty years, the dominant strategy in American healthcare has been vertical consolidation: hospital systems buying up physician practices, imaging centers, and infusion clinics, then rebadging them as "hospital outpatient departments." The point was never the real estate. The point was the billing code. The same scan, the same infusion, the same office visit pays substantially more the moment it happens under a hospital license — Medicare tacks on a facility fee that a freestanding physician office cannot charge. That spread is what financed the acquisition wave that turned independent medicine into an employed profession.
The second markup is less visible but bigger. Under the 340B program, created in 1992 to help safety-net hospitals, eligible hospitals buy outpatient drugs at steep statutory discounts — and then bill Medicare at the average sales price plus 6%. The spread between what the hospital pays and what Medicare reimburses became one of the most reliable profit engines in nonprofit medicine. The program has grown far beyond its safety-net origins; CMS's own analysis found cases where a beneficiary's copay alone exceeded what the hospital paid for the entire drug.
The 2027 rule attacks both.
On site-neutrality, CMS is extending the equalization it began in 2026. Last year's rule cut drug administration services at off-campus hospital outpatient departments to physician-office rates — roughly $7 billion in federal savings and $5 billion in beneficiary savings over a decade. The 2027 proposal adds imaging without contrast: X-rays and basic scans at hospital-owned outpatient sites would be paid at the same rate as at an independent imaging center, saving about $260 million in Part B spending in year one. The Committee for a Responsible Federal Budget, working from CBO data, puts the ten-year figure near $10 billion, plus roughly $7 billion in reduced beneficiary premiums and cost-sharing.
On 340B, CMS proposes cutting reimbursement from average sales price plus 6% to average sales price minus 33.4% — a swing of nearly 40 percentage points, worth about $5.7 billion in reduced drug spending in 2027 alone and $1.15 billion in beneficiary out-of-pocket savings. CMS tried a version of this in 2017 at minus 22.5%, and the Supreme Court struck it down in 2022 because the agency hadn't surveyed hospitals' actual acquisition costs. This time CMS ran the survey first. The minus 33.4% figure is built from the data the Court said was missing — this proposal was engineered to survive litigation.
The rule also continues dismantling the inpatient-only list — 638 more procedures proposed to move out in 2027, year two of a three-year phase-out — and keeps expanding what ambulatory surgery centers are allowed to perform. Every piece points the same direction: Medicare no longer wants to pay extra for the word "hospital."
The hospital lobby's reaction was immediate. America's Essential Hospitals said the rule "takes an axe to critical funding that supports essential hospitals." That's the loser's side of the ledger. But here's the detail that matters for investors and that the headlines have mostly missed: because the outpatient payment system is budget-neutral, the $5.7 billion cut from 340B drugs doesn't leave Medicare's outpatient pool at all. It gets redistributed — recycled into higher base rates for every hospital's non-drug services. The money doesn't disappear. It moves.
The question is where.
The rest of this briefing is for paid members: the budget-neutrality mechanics that turn a Medicare cut into a windfall for one class of hospital operator, the three listed names positioned on the receiving side (including the one whose management just called this reallocation potentially "material" on its July earnings call), the imaging pure-play the site-neutral change quietly promotes, the litigation and exemption risk map with the one date that decides it, and the bottom-line positioning framework.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.